Dual Pathway Inhibition in the Cardiometabolic Patient: How Effective Is the Combination of Rivaroxaban and Aspirin?
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Deepak Bhatt
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Deepak Bhatt
498 views
May 19, 2021
Comments 0
Login to view comments.
Click here to Login